4//SEC Filing
Lenz Robert A. 4
Accession 0001610717-24-000505
CIK 0001885522other
Filed
Oct 10, 8:00 PM ET
Accepted
Oct 11, 4:10 PM ET
Size
7.1 KB
Accession
0001610717-24-000505
Insider Transaction Report
Form 4
Lenz Robert A.
Head of R&D
Transactions
- Sale
Common Stock
2024-10-10$15.09/sh−8,260$124,603→ 314,706 total - Sale
Common Stock
2024-10-09$15.01/sh−5,563$83,507→ 322,966 total
Footnotes (3)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024.
- [F2]This transaction was executed in multiple trades in prices ranging from $15.00 to $15.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $15.00 to 15.2435, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Neumora Therapeutics, Inc.
CIK 0001885522
Entity typeother
Related Parties
1- filerCIK 0001992908
Filing Metadata
- Form type
- 4
- Filed
- Oct 10, 8:00 PM ET
- Accepted
- Oct 11, 4:10 PM ET
- Size
- 7.1 KB